CoChat
Sign Up
Cited by 83

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease

Parsi, Sepideh, Smith, Pascal Y, Goupil, Claudia, Dorval, Véronique, Hébert, Sébastien S·2015·Molecular Therapy - Nucleic Acids
DOI 10.1038/mtna.2015.33PMC PMC4881761
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mtna.2015.33

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 6 references

Research works printed but not linked: 86

  1. Sperling, 2011, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 280, 10.1016/j.jalz.2011.03.003 · DOI · Paper page
  2. De Strooper, 2012, Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease, Cold Spring Harb Perspect Med, 2, a006304, 10.1101/cshperspect.a006304 · DOI
  3. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  4. Jia, 2014, Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials, Biomed Res Int, 2014, 837157, 10.1155/2014/837157 · DOI
  5. Boutajangout, 2014, Tau-based therapeutic approaches for Alzheimer's disease - a mini-review, Gerontology, 60, 381, 10.1159/000358875 · DOI
  6. Rosenblum, 2014, Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult, Neurobiol Aging, 35, 969, 10.1016/j.neurobiolaging.2013.10.085 · DOI
  7. Jaturapatporn, 2012, Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease, Cochrane Database Syst Rev, 2, CD006378
  8. Carreiras, 2013, The multifactorial nature of Alzheimer's disease for developing potential therapeutics, Curr Top Med Chem, 13, 1745, 10.2174/15680266113139990135 · DOI
  9. Hébert, 2013, A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls, J Alzheimers Dis, 35, 335, 10.3233/JAD-122350 · DOI · Paper page
  10. Ambros, 2004, The functions of animal microRNAs, Nature, 431, 350, 10.1038/nature02871 · DOI · Paper page
  11. He, 2004, MicroRNAs: small RNAs with a big role in gene regulation, Nat Rev Genet, 5, 522, 10.1038/nrg1379 · DOI · Paper page
  12. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  13. van Rooij, 2014, Development of microRNA therapeutics is coming of age, EMBO Mol Med, 6, 851, 10.15252/emmm.201100899 · DOI · Paper page
  14. Ling, 2013, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nat Rev Drug Discov, 12, 847, 10.1038/nrd4140 · DOI
  15. Jackson, 2012, Developing microRNA therapeutics: approaching the unique complexities, Nucleic Acid Ther, 22, 213, 10.1089/nat.2012.0356 · DOI
  16. Hammond, 2007, MicroRNAs as tumor suppressors, Nat Genet, 39, 582, 10.1038/ng0507-582 · DOI
  17. Bader, 2010, The promise of microRNA replacement therapy, Cancer Res, 70, 7027, 10.1158/0008-5472.CAN-10-2010 · DOI
  18. Simonson, 2015, MicroRNA Therapeutics: the Next Magic Bullet?, Mini Rev Med Chem, 15, 467, 10.2174/1389557515666150324123208 · DOI
  19. Bader, 2012, miR-34 - a microRNA replacement therapy is headed to the clinic, Front Genet, 3, 120, 10.3389/fgene.2012.00120 · DOI
  20. Pasquinelli, 2012, MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship, Nat Rev Genet, 13, 271, 10.1038/nrg3162 · DOI
  21. Finnerty, 2010, The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases, J Mol Biol, 402, 491, 10.1016/j.jmb.2010.07.051 · DOI · Paper page
  22. Linsley, 2007, Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression, Mol Cell Biol, 27, 2240, 10.1128/MCB.02005-06 · DOI · Paper page
  23. Müller, 2014, MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid, Neurobiol Aging, 35, 152, 10.1016/j.neurobiolaging.2013.07.005 · DOI · Paper page
  24. Liu, 2012, MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice, Neurobiol Aging, 33, 522, 10.1016/j.neurobiolaging.2010.04.034 · DOI
  25. Wang, 2011, Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter, Acta Neuropathol, 121, 193, 10.1007/s00401-010-0756-0 · DOI · Paper page
  26. Hébert, 2008, Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression, Proc Natl Acad Sci USA, 105, 6415, 10.1073/pnas.0710263105 · DOI · Paper page
  27. Shioya, 2010, Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3, Neuropathol Appl Neurobiol, 36, 320, 10.1111/j.1365-2990.2010.01076.x · DOI · Paper page
  28. Nunez-Iglesias, 2010, Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation, PLoS One, 5, e8898, 10.1371/journal.pone.0008898 · DOI
  29. Hébert, 2010, Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration, Hum Mol Genet, 19, 3959, 10.1093/hmg/ddq311 · DOI
  30. Ai, 2013, MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats, J Neurosci, 33, 3989, 10.1523/JNEUROSCI.1997-12.2013 · DOI
  31. Wang, 2008, The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1, J Neurosci, 28, 1213, 10.1523/JNEUROSCI.5065-07.2008 · DOI · Paper page
  32. Nelson, 2010, MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study, J Alzheimers Dis, 21, 75, 10.3233/JAD-2010-091603 · DOI · Paper page
  33. Smith, 2011, In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs, J Neurochem, 116, 240, 10.1111/j.1471-4159.2010.07097.x · DOI · Paper page
  34. Zhu, 2012, MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1, Brain Res Bull, 88, 596, 10.1016/j.brainresbull.2012.05.018 · DOI · Paper page
  35. van Rooij, 2012, Developing microRNA therapeutics, Circ Res, 110, 496, 10.1161/CIRCRESAHA.111.247916 · DOI · Paper page
  36. Jopling, 2010, Targeting microRNA-122 to Treat Hepatitis C Virus Infection, Viruses, 2, 1382, 10.3390/v2071382 · DOI
  37. Patel, 2008, MicroRNAs can regulate human APP levels, Mol Neurodegener, 3, 10, 10.1186/1750-1326-3-10 · DOI
  38. Absalon, 2013, MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons, J Neurosci, 33, 14645, 10.1523/JNEUROSCI.1327-13.2013 · DOI · Paper page
  39. Ancolio, 1999, Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 –> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease, Proc Natl Acad Sci USA, 96, 4119, 10.1073/pnas.96.7.4119 · DOI
  40. Planel, 2008, Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo, J Neurosci, 28, 12798, 10.1523/JNEUROSCI.4101-08.2008 · DOI · Paper page
  41. Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc Natl Acad Sci USA, 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
  42. Wilkes, 2014, Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency, J Pain Res, 7, 571, 10.2147/JPR.S46929 · DOI
  43. Grondin, 2015, Onset Time and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA, Mol Ther Nucleic Acids, 4, e245, 10.1038/mtna.2015.20 · DOI
  44. Wesemann, 2014, Clinical accuracy and safety using the SynchroMed II intrathecal drug infusion pump, Reg Anesth Pain Med, 39, 341, 10.1097/AAP.0000000000000107 · DOI
  45. Dweep, 2011, miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes, J Biomed Inform, 44, 839, 10.1016/j.jbi.2011.05.002 · DOI
  46. Zhou, 2012, miR-16 targets transcriptional corepressor SMRT and modulates NF-kappaB-regulated transactivation of interleukin-8 gene, PLoS One, 7, e30772, 10.1371/journal.pone.0030772 · DOI
  47. Frasca, 2015, MicroRNAs miR-155 and miR-16 Decrease AID and E47 in B Cells from Elderly Individuals, J Immunol, 195, 2134, 10.4049/jimmunol.1500520 · DOI · Paper page
  48. Padurariu, 2012, Hippocampal neuronal loss in the CA1 and CA3 areas of Alzheimer's disease patients, Psychiatr Danub, 24, 152
  49. Grinberg, 2011, Brainstem: neglected locus in neurodegenerative diseases, Front Neurol, 2, 42, 10.3389/fneur.2011.00042 · DOI
  50. Simic, 2009, Does Alzheimer's disease begin in the brainstem?, Neuropathol Appl Neurobiol, 35, 532, 10.1111/j.1365-2990.2009.01038.x · DOI · Paper page
  51. Wiese, 2007, Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research, Proteomics, 7, 340, 10.1002/pmic.200600422 · DOI
  52. Warde-Farley, 2010, The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function, Nucleic Acids Res, 38, W214, 10.1093/nar/gkq537 · DOI · Paper page
  53. Huang, 2009, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat Protoc, 4, 44, 10.1038/nprot.2008.211 · DOI · Paper page
  54. Wang, 2010, miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease, Am J Pathol, 177, 334, 10.2353/ajpath.2010.091202 · DOI
  55. Ren, 2012, Identification and characterization of receptor-specific peptides for siRNA delivery, ACS Nano, 6, 8620, 10.1021/nn301975s · DOI
  56. Trang, 2011, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol Ther, 19, 1116, 10.1038/mt.2011.48 · DOI
  57. Di Martino, 2014, In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma, PLoS One, 9, e90005, 10.1371/journal.pone.0090005 · DOI
  58. Thomson, 2013, On measuring miRNAs after transient transfection of mimics or antisense inhibitors, PLoS One, 8, e55214, 10.1371/journal.pone.0055214 · DOI
  59. Zhang, 2013, Progress in microRNA delivery, J Control Release, 172, 962, 10.1016/j.jconrel.2013.09.015 · DOI · Paper page
  60. Robakis, 2014, Cell signaling abnormalities may drive neurodegeneration in familial Alzheimer disease, Neurochem Res, 39, 570, 10.1007/s11064-013-1003-6 · DOI
  61. Magen, 2014, Oligonucleotide-based therapy for neurodegenerative diseases, Brain Res, 1584, 116, 10.1016/j.brainres.2014.04.005 · DOI
  62. Hanbury, 2003, GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults, J Comp Neurol, 461, 307, 10.1002/cne.10667 · DOI
  63. Furman, 2012, Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease, J Neurosci, 32, 16129, 10.1523/JNEUROSCI.2323-12.2012 · DOI · Paper page
  64. Hol, 2003, Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms, Mol Psychiatry, 8, 786, 10.1038/sj.mp.4001379 · DOI
  65. Meraz-Ríos, 2013, Inflammatory process in Alzheimer's Disease, Front Integr Neurosci, 7, 59, 10.3389/fnint.2013.00059 · DOI · Paper page
  66. An, 2012, miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure, Apoptosis, 17, 702, 10.1007/s10495-012-0704-7 · DOI
  67. Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 · DOI · Paper page
  68. Nonaka, 2010, Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases, J Biol Chem, 285, 34885, 10.1074/jbc.M110.148460 · DOI
  69. Raven, 2013, Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging, J Alzheimers Dis, 37, 127, 10.3233/JAD-130209 · DOI · Paper page
  70. Huang, 2014, Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease, Neurobiol Aging, 35, 1045, 10.1016/j.neurobiolaging.2013.11.004 · DOI
  71. Hunker, 2006, Rab5-activating protein 6, a novel endosomal protein with a role in endocytosis, Biochem Biophys Res Commun, 340, 967, 10.1016/j.bbrc.2005.12.099 · DOI
  72. Leto, 2012, Regulation of glucose transport by insulin: traffic control of GLUT4, Nat Rev Mol Cell Biol, 13, 383, 10.1038/nrm3351 · DOI · Paper page
  73. Blencowe, 1998, A coactivator of pre-mRNA splicing, Genes Dev, 12, 996, 10.1101/gad.12.7.996 · DOI
  74. Shehadeh, 2010, SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease, PLoS One, 5, e9104, 10.1371/journal.pone.0009104 · DOI
  75. Liang, 2007, Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain, Physiol Genomics, 28, 311, 10.1152/physiolgenomics.00208.2006 · DOI
  76. Baskerville, 2008, Aging elevates metabolic gene expression in brain cholinergic neurons, Neurobiol Aging, 29, 1874, 10.1016/j.neurobiolaging.2007.04.024 · DOI
  77. Junn, 2012, MicroRNAs in neurodegenerative diseases and their therapeutic potential, Pharmacol Ther, 133, 142, 10.1016/j.pharmthera.2011.10.002 · DOI · Paper page
  78. Park, 2010, Analysis of microRNA knockouts in mice, Hum Mol Genet, 19, R169, 10.1093/hmg/ddq367 · DOI
  79. Vidigal, 2015, The biological functions of miRNAs: lessons from in vivo studies, Trends Cell Biol, 25, 137, 10.1016/j.tcb.2014.11.004 · DOI
  80. Aqeilan, 2010, miR-15a and miR-16-1 in cancer: discovery, function and future perspectives, Cell Death Differ, 17, 215, 10.1038/cdd.2009.69 · DOI
  81. Yang, 2014, MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway, Cancer Sci, 105, 265, 10.1111/cas.12351 · DOI
  82. Chen, 2013, miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma, FEBS Lett, 587, 1366, 10.1016/j.febslet.2013.03.007 · DOI
  83. Calin, 2008, MiR-15a and miR-16-1 cluster functions in human leukemia, Proc Natl Acad Sci USA, 105, 5166, 10.1073/pnas.0800121105 · DOI
  84. Hébert, 2009, MicroRNA regulation of Alzheimer's Amyloid precursor protein expression, Neurobiol Dis, 33, 422, 10.1016/j.nbd.2008.11.009 · DOI · Paper page
  85. Dorval, 2014, Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models, PLoS One, 9, e85510, 10.1371/journal.pone.0085510 · DOI
  86. Wang, 2010, Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes, RNA, 16, 394, 10.1261/rna.1905910 · DOI

Cited by

Sorted by citations

See all 83

Metadata

Authors
Parsi, S., Smith, P. Y., Goupil, C., Dorval, V., & Hébert, S. S.
Venue
Molecular Therapy - Nucleic Acids
Publisher
Elsevier BV
Published
2015
Volume
4
Pages
e256
ISSN
2162-2531
DOI
10.1038/mtna.2015.33
PMC
PMC4881761
Cited by
83
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review